Triumph Research Intelligence (TRI), a Cambridge, UK, and Raleigh, North Carolina-based global provider of Risk-Based Monitoring (RBM) solutions for clinical trials, closed a growth capital investment of undisclosed amount.
Funding was raised through Octopus Investments, part of the Octopus Group headquartered in London.
The company intends to use the funds to accelerate development of its core technology platform, OPRA, and expand its international presence.
Founded in 2014 and led by Duncan Hall, CEO,, TRI developed cloud-based software for RBM, enabling early risk detection, improved data quality, increased operational efficiency and compliance with regulatory requirements.
Clients include pharmaceutical companies, Clinical Research Organisations (CROs) and BioTech start-ups who operate within the broader clinical trials market.